Роль цитокинов в патогенезе аутоиммунного диабета, вопросы иммуноинтервенции
https://doi.org/10.20538/1682-0363-2010-1-76-83
Аннотация
Рассмотрена роль цитокинов в патогенезе аутоиммунного сахарного диабета, включая латентный аутоиммунный диабет взрослых. Обсуждаются терапевтические подходы, направленные на предупреждение снижения секреции эндогенного инсулина. Приведен обзор клинических испытаний иммуносупрессивных средств и модуляторов иммунологической толерантности при аутоиммунном сахарном диабете (типа 1А).
Об авторах
Е. Б. Кравец
Сибирский государственный медицинский университет
Россия
Россия
д-р мед. наук, профессор, зав. кафедрой эндокринологии и диабетологии
Т. В. Саприна
Сибирский государственный медицинский университет
Россия
канд. мед. наук, доцент кафедры эндокринологии и диабетологии
Россия
канд. мед. наук, доцент кафедры эндокринологии и диабетологии
Ф. Э. Лазаренко
Сибирский государственный медицинский университет
Россия
Россия
Лазаренко Феликс Эдуардович, аспирант кафедры эндокринологии и диабетологии
тел. (382-2) 42-79-80, 8-913-851-7144, e-mail: eliksi@sibmail.com
Т. С. Прохоренко
Сибирский государственный медицинский университет
Россия
аспирант кафедры фундаментальных основ клинической медицины
Россия
аспирант кафедры фундаментальных основ клинической медицины
Н. В. Рязанцева
Сибирский государственный медицинский университет
Россия
д-р мед. наук, профессор, зав. кафедрой фундаментальных основ клинической медицины
Россия
д-р мед. наук, профессор, зав. кафедрой фундаментальных основ клинической медицины
Список литературы
1. Балаболкин М.И. Неотложные проблемы современной эндокринологии//Медицина. 2006. № 3. С. 10-14.
2. Зак К.П., Малиновская Т.Н., Тронько Н.Д. Иммунитет у детей, больных сахарным диабетом. Киев: Книга плюс, 2002. 111 с.
3. Попова В.В., Мельниченко С.В., Лукашова Р.Г. и др. Содержание различных цитокинов в крови здоровых детей-сибсов, позитивных и негативных по наличию диабет-ассоциированных аутоантител (GADA, IA-2A, IAA)//Врачеб. дело. 2003. T. 8. C. 26-29.
4. Попова В.В., Мельниченко С.В., Малиновская Т.Н. и др. Содержание цитокинов в крови в доклиническую и раннюю клиническую стадии развития сахарного диабета у детей//Проблеми ендокринної патології. 2004. T. 2. C. 53-59.
5. Смирнова О.М., Кононенко И.В., Дедов И.И. Аутоиммунный латентный сахарный диабет у взрослых//Проблемы эндокринологии. 2008. Т. 54, № 2. С. 1-7.
6. Agardh C.D., Corrado C.M., Lethagen Е. et al. Clinical evidence for safety of GAD65 immunomodulation in adult-onset autoimmune diabetes//J. of Diabetes and its Complications. 2005. V. 19, № 4. P. 238-246.
7. Allen J.E., Maizels R.M. Th1-Th2: reliable paradigm or dangerous dogma?//Immunol. Today. 1997. V. 18. P. 387-392
8. Bloomgarden Z.T. Immunologic Issues in Type 1 Diabetes//Diabetes Care. 2001. V. 24. P. 2143-2148.
9. Bonato V., Dionisi S., Vendrame F. et al. Oral probiotic administration in the NOD mouse induces systemic and islet IL-10 production and down regulates pancreatic expression of proinflammatory cytokine and chemokines//Diabetologia. 2005. V. 48, Suppl. 1. А 193.
10. Bougneres P.F., Carel J.C., Castano L. et al. Factors associated with early remission of type 1 diabetes in children treated with cyclosporine//N. Engl. J. Med. 1988. V. 318. P. 663-670.
11. Bruun C., Heding P.E., Ronn S.G. et al. Inhibitory effects of suppressor of cytokine signalling-3 on tumor necrosis factor-alpha induced signalling in pancreatic beta cells//Diabetologia. 2005. V. 48 (Suppl. 1): А181.
12. Campbell I.L., Wong G.H., Schrader J.W. et al. Interferon-gamma enhances the expression of the major histocompatibility class I antigens on mouse pancreatic beta cells//Diabetes. 1985. V. 34. P. 1205-1210.
13. Chang Y., Piao S.L., Gao S. et al. Regulatory effects of micronutrient complex on the expression of Th1and Th2 cytokines in diabetic C57BL mice//Wei Sheng Yan Jiu. 2005. V. 34, № 1. P. 64-66.
14. Chen M., Yang Z.D., Zmith K.M. et al. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity//Diabetologia. 2005. V. 48, № 3. P. 486-495.
15. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus//The New England Journal of Medicine. 1993. V. 329. P. 977-986.
16. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus//The New England Journal of Medicine. 2002. V. 346, № 22. P. 1685-1691.
17. Durinovic-Bello I., Riedl M., Rosinger S. et al. Th2 dominance of T helper cell response to preproinsulin in individuals with preclinical type 1 diabetes//Ann. N. Y. Acad. Sci. 2002. V. 958. P. 209-213.
18. Erbagci A.B., Tarakcioglu M., Coskun Y. et al. Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children//Clin. Biochem. 2001. V. 34, № 8. P. 645-650.
19. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes//Lancet. 2004. V. 363. P. 925-931.
20. Geissler A., Schneider M.L., Bochow B. et al. Regulation of IL-10 release from peripherial blood cells by epinephrine in disturbed in DM type 1//Diabetologia. 1999. V. 42, Suppl. 1. А 101.
21. Groop L., Bottazzo G.F., Doniach D. Islet cell antibodies identify latent tipe 1 diabetes in patient aged 35-75 years at diagnosis//Diabetes. 1986. V. 35. P. 237-241.
22. Hanifi-Moghaddam P., Schloot N.C., Kappler S. et al. An association of autoantibody status and serum cytokine levels in type 1 diabetes//Diabetes. 2003. V. 52, № 5. P. 1137-1142.
23. Herold K.C., Burton J.B., Francois F. et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)//J. Clin. Invest. 2003. V. 111, № 3. P. 409-418.
24. Herold K.C., Hagopian W., Auger J.A. et al. Anti-CD3 monoclonal antibody in new-onset 1 diabetes mellitus//The New England Journal of Medicine. 2002. V. 346, № 22. P. 1692-1698.
25. Hohmeier H.E., Tran W., Chen G. et al. Inflammatory mechanisms in diabetes: lessons from the β-cell//Int. J. Obesity. 2003. V. 27. P. 12-16.
26. Hussain M.J., Maher J., Warnock T. et al. Cytokine overproduction in healthy first degree relatives of patients with IDDM//Diabetologia. 1998. V. 41, № 3. P. 343-349.
27. Hussain M.J., Peakman M., Gallati H. et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM//Diabetologia. 1996. V. 39, № 1. P. 60-69.
28. Karlsson Faresjo M.G., Ernerudh J., Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1diabetes//Scand. J. Immunol. 2004. V. 59, № 5. P. 517-526.
29. Karlsson Faresjo M.G., Lawesson S.S., Ludvigsson J. Th1-like dominance high risk first-degree relatives of type I diabetic patients//Diabetologia. 2000. V. 43, № 6. P. 742-749.
30. Kelso A. Th1 and Th2 subsets: paradigms lost?//Immunol. Today. 1995. V. 16. P. 374-379.
31. Keymeulen B., Vandemeulebroucke E., Ziegler A.G. et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes//The New England Journal of Medicine. 2005. V. 352, № 25. P. 2598-2608.
32. Klementova M., Wohl P., Krusinova E. et al. Circadian variation in urinary excretion of TNFα-soluble receptor 1 and TNFα-soluble receptor 2 in type 1 diabetes mellitus//Diabetologia. 2004. V. 47, Suppl. 1. A 461.
33. Kretowski A., Mironczuk K., Karpinska A. et al. Interleukin-18 promoter polymorphisms in type 1 diabetes//Diabetes. 2002. V. 51. P. 3347-3349.
34. Kukreja A., Maclaren N.K. Autoimmunity and diabetes//J. Clin. Endocrinol. Metab. 1999. V. 84, № 12. P. 4371-4378.
35. Kulseng B., Skjak-Braek G., Folling I. et al. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide//Scand. J. Immunol. 1996. V. 43, № 3. P. 335-340
36. Leech N.J., Elsegood K.A., Narendran P. et al. Deficit in Th2 cytokine production from peripheral T cell subsets in recent onset type 1diabetes//Abstr. Book 4th Immunol. Diabet. Soc. Congr. November 12-15, 1999. Rome. P. 75.
37. Leech N.J., Elsegood K.A., Narendran P. et al. T helper 1 profile of recently activated circulating T cells in type 1 diabetes//Diabetologia. 1999. V. 42, Suppl. 1. A 316.
38. Leslie R.D., Williams R., Pozzilli P. et al. Type 1 diabetes and latent autoimmune diabetes in adults (LADA): one end of the rainbow//J. Clin. Endocrinol. Metab. 2006. V. 91, № 5. P. 1654-1659.
39. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes//Biochem. Pharmacol. 2003. V. 66, № 8. P. 1433-1440.
40. Marchase R.B., Chen P.Y., Su Z. et al. Lymphocytes from subjects with type 1diabetes are deficient in capacitative calcium entry: implications to immune function, cytokine production, and T cell subset representation//Abstr. Book 4th Immunol. Diabet. Soc. Congr. November 12-15, 1999. Rome. P. 82.
41. Movahedi B., Van de Casteele M., Caluwe N. et al. Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells//Diabetologia. 2004. V. 47, № 6. P. 998-1008.
42. Nicoletti F., Conget I., Di Marco R. et al. Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing Type I diabetes//Diabetologia. 2001. V. 44, № 3. P. 309-311.
43. Novota P., Kolostova K., Pinterova D. et al. Interleukin IL-18 gene promoter polymorphisms in adult patients with type 1 diabetes mellitus and latent autoimmune diabetes in adults//Immunology Letters. 2005. V. 96, № 2. P. 247-251.
44. Pravica V., Asderakis A., Perrey C. et al. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene//Eur. J. Immunogenet. 1999. V. 26. P. 1-3.
45. Pravica V., Perrey C., Stevens A. et al. A single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ gene//Hum. Immunol. 2000. V. 61. P. 863-866.
46. Rabinovitch A., Suarez-Pinzon W., El-Sheikh A. et al. Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM//Diabetes. 1996. V. 45. P. 749-754.
47. Rabinovitch A., Suarez-Pinzon W., Sorensen O. et al. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice//J. Immunol. 1995. V. 154. P. 4874-4882.
48. Rapoport M.J., Bistritzer T., Aharoni D. et al. Th/Th2 cytokine secretion of first degree relatives of T1DM patients//Cytokine. 2005. V. 30, № 5. P. 219-227.
49. Rapoport M.J., Mor A., Vardi P. et al. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus//J. Autoimmun. 1998. V. 11, № 6. P. 635-642.
50. Sarvetnick N., Liggitt D., Pitts S.L. et al. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma//Cell. 1988. V. 52. P. 773-777.
51. Sountsov Y.I., Dedov I.I., Shestakova M.V. Screening of diabetes mellitus complications as a method of evaluate the quality of patient care. Ministry of Health and Social Development of the Russian Federation. FSE Research Centre of Endocrinology. 2008.
52. Stenström G., Gottsäter A., Bakhtadze E. et al. Latent Autoimmune Diabetes in Adults//Diabetes. 2005. V. 54, Suppl. 2, PS. 68-72.
53. Storling I., Binzer J., Andersson A.K. et al. Nitric oxide causes activation of JNK suppression of Akt in insulin-secreting cells//Diabetologia. 2005. V. 48, Suppl. 1. A. 38.
54. Storling I., Binzer J., Andersson A.K. et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt//Diabetologia. 2005. V. 48, № 10. P. 2039-2050.
55. Szebeni A., Schloot N., Kecskemeti V. et al. Th1and Th2 cell responses of type 1diabetes patients and healthy controls to human heat-shock protein 60 peptides AA437-460 and AA394-408//Inflamm. Res. 2005. V. 54, № 10. P. 415-419.
56. The Canadian-European Randomized Control Trial Group. Cyclosporin -induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion//Diabetes. 1988. V. 37. P. 1574-1582.
57. Torn C., Hillman M., Sanjeevi C.B. et al. TNF-α RII in relation to type 1diabetes and latent autoimmune diabetes in adults//Diabetologia. 2003. V. 46, Suppl. 2. A. 108.
58. Tovo P.A., Cerutti F., Palomba E. et al. Evidence of circulating interferon-gamma in newly diagnosed diabetic children//Acta Paediatr. Scand. 1984. V. 73, № 6. P. 785-788.
59. Tsiavou A., Hatziagelaki E., Chaidaroglou A. et al. Correlation between intracellular interferon-gamma (IFN-gamma) production by CD4+ and CD8+ lymphocytes and IFN-gamma gene polymorphism in patients with type 2 diabetes mellitus and latent autoimmune diabetes of adults (LADA)//Cytokine. 2005. V. 31, № 2. P. 135-141.
60. Tsiavou A., Hatziagelaki E., Chaidaroglou A. et al. TNF-alpha, TGF-beta1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus//J. Clin. Immunol. 2004. V. 24, № 6. P. 591-599.
61. Zaccone P., Phillips J., Conget I. et al. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse//Clin. Immunol. 2005. V. 115, № 1. P. 74-79.
Рецензия
Для цитирования:
Кравец Е.Б., Саприна Т.В., Лазаренко Ф.Э., Прохоренко Т.С., Рязанцева Н.В. Роль цитокинов в патогенезе аутоиммунного диабета, вопросы иммуноинтервенции. Бюллетень сибирской медицины. 2010;9(1):76-83. https://doi.org/10.20538/1682-0363-2010-1-76-83
For citation:
Kravets Ye.B., Saprina T.V., Lazarenko F.E., Prokhorenko T.S., Ryazantseva N.V. The role of cytokines in the pathogenesis of autoimmune diabetes, immune intervention issues. Bulletin of Siberian Medicine. 2010;9(1):76-83. (In Russ.) https://doi.org/10.20538/1682-0363-2010-1-76-83
Просмотров:
534
Послать статью по эл. почте 